[Cytokine targetting therapy for inflammatory bowel diseases].
Matsumoto
Takayuki
T
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D001379:Azathioprine / Q000627:therapeutic use; D003093:Colitis, Ulcerative / Q000276:immunology / Q000628:therapy*; D003424:Crohn Disease / Q000276:immunology / Q000628:therapy*; D016207:Cytokines / Q000276:immunology*; D004359:Drug Therapy, Combination; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D000069285:Infliximab; D019947:Receptors, Interleukin-6 / Q000276:immunology; D016540:Smoking Cessation; D014409:Tumor Necrosis Factor-alpha / Q000276:immunology
D000911:Antibodies, Monoclonal; D016207:Cytokines; D007166:Immunosuppressive Agents; D019947:Receptors, Interleukin-6; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D001379:Azathioprine